Effect of a newly developed ready-to-use supplementary food on growth indicators in children with mild to moderate malnutrition

Azimi, F. and Esmaillzadeh, A. and Alipoor, E. and Moslemi, M. and Yaseri, M. and Hosseinzadeh-Attar, M.J. (2020) Effect of a newly developed ready-to-use supplementary food on growth indicators in children with mild to moderate malnutrition. Public Health, 185. pp. 290-297.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....


Objectives: Malnutrition is one of the leading causes of death among children younger than five years. In this study, we aimed to formulate a ready-to-use supplementary food (RUSF), based on local food products, and investigate its efficacy on growth indicators in children with mild to moderate malnutrition. Study design: This is a randomized controlled clinical trial. Methods: This study was performed in six health centers in Shahr-e-Rey, Tehran, Iran, between April and October 2017. One hundred children, aged 24�59 months, with mild to moderate malnutrition (weight-for-height Z-score WHZ between �3 and �1) were randomly assigned to two groups to receive either 1�3 sachets of RUSF or normal diet for 8 weeks. All mothers and caregivers received nutrition education. Growth indicators including weight and height, WHZ, and body mass index (BMI), along with clinical outcomes, were assessed. Results: Children who received RUSF had a significant increase in weight (1.44 ± 0.38 vs 0.7 ± 0.32 kg, respectively, P < 0.001), and BMI (1.2 ± 0.47 vs 0.35 ± 0.33 kg/m2, respectively, P < 0.001) compared with the control group. There was a greater daily weight gain during the first 4 weeks (P < 0.001) and throughout the study (P = 0.013) in the RUSF group. Daily height gain was considerably higher in the RUSF group during the first 4 weeks (P = 0.027). Children in the RUSF group had more improvement in WHZ (1.18 ± 0.41 vs 0.41 ± 0.31, P < 0.001) after supplementation. Besides, 92% of the RUSF and 12% of the control group reached to WHZ > �1 at the end of the study (P < 0.001). There was lower prevalence of diarrhea (12% vs 28.6%, respectively, P = 0.01) and marginally lower fever (16% vs 36.7%, respectively, P = 0.05) in the intervention than in the control group. Conclusions: A newly developed RUSF improved growth indicators and clinical outcomes in children with mild to moderate malnutrition. Clinical Trial Registry number: IRCT2017021315536N6 (registered at www.irct.ir) © 2020 The Royal Society for Public Health

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: child health; diarrheal disease; disease prevalence; food product; food supplementation; growth rate; malnutrition, Article; body height; body mass; body weight; body weight gain; child; clinical effectiveness; clinical feature; controlled study; developmental, age and growth parameters; diarrhea; disease assessment; disease severity; female; fever; growth indicator; human; Iran; major clinical study; male; malnutrition; nutrition education; preschool child; prevalence; randomized controlled trial; ready to use supplementary food; therapy effect; weight for height Z score, Iran; Tehran Iran
Subjects: WB Practice of Medicine
WS Pediatrics
Depositing User: eprints admin
Date Deposited: 22 Sep 2020 09:12
Last Modified: 22 Sep 2020 09:12
URI: http://eprints.iums.ac.ir/id/eprint/23212

Actions (login required)

View Item View Item